AMRX vs COP · P/E 44, rev $2.79B vs P/E 19, rev $58.94B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus ConocoPhillips (COP) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Not investment advice. Open the AMRX and COP stock pages for the full models.
Not investment advice.